Amphastar Pharmaceuticals, Inc. $AMPH Shares Sold by Trexquant Investment LP

Key Points

• Trexquant Investment LP reduced its stake in Amphastar Pharmaceuticals by 13.5%, selling 14,237 shares, and now holds approximately 91,291 shares valued at $2.65 million.
• Institutional investors collectively own 65.09% of Amphastar Pharmaceuticals, with several firms dramatically increasing their positions, including GAMMA Investing LLC, which raised its holdings by 4,151.3%.
• Analysts have adjusted their price targets for Amphastar Pharmaceuticals, with Wells Fargo dropping its target from $40.00 to $35.00, while Needham & Company upgraded the stock from a "hold" to a "buy" rating with a target of $36.00.

Trexquant Investment LP reduced its position in shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH - Free Report) by 13.5% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 91,291 shares of the company's stock after selling 14,237 shares during the period. Trexquant Investment LP owned 0.19% of Amphastar Pharmaceuticals worth $2,647,000 at the end of the most recent quarter.

Other large investors have also recently made changes to their positions in the company. Signaturefd LLC increased its holdings in shares of Amphastar Pharmaceuticals by 147.7% during the 1st quarter. Signaturefd LLC now owns 872 shares of the company's stock worth $25,000 after buying an additional 520 shares during the last quarter. GF Fund Management CO. LTD. bought a new stake in shares of Amphastar Pharmaceuticals in the 4th quarter valued at about $38,000. Tower Research Capital LLC TRC grew its position in Amphastar Pharmaceuticals by 43.7% in the fourth quarter. Tower Research Capital LLC TRC now owns 1,145 shares of the company's stock valued at $43,000 after purchasing an additional 348 shares in the last quarter. IFP Advisors Inc bought a new stake in Amphastar Pharmaceuticals in the 1st quarter valued at $34,000. Finally, GAMMA Investing LLC lifted its stake in Amphastar Pharmaceuticals by 46.6% in the 1st quarter. GAMMA Investing LLC now owns 1,333 shares of the company's stock valued at $39,000 after purchasing an additional 424 shares during the last quarter. 65.09% of the stock is owned by institutional investors and hedge funds.

Amphastar Pharmaceuticals Stock Performance

Shares of NASDAQ AMPH traded down $0.04 during midday trading on Monday, hitting $29.38. The company's stock had a trading volume of 203,500 shares, compared to its average volume of 566,947. The stock has a fifty day moving average price of $25.21 and a 200 day moving average price of $25.67. The firm has a market capitalization of $1.37 billion, a price-to-earnings ratio of 11.01 and a beta of 0.80. Amphastar Pharmaceuticals, Inc. has a one year low of $20.39 and a one year high of $53.96. The company has a current ratio of 3.29, a quick ratio of 2.21 and a debt-to-equity ratio of 0.80.

Analyst Ratings Changes

A number of equities analysts have recently issued reports on AMPH shares. Needham & Company LLC upgraded Amphastar Pharmaceuticals from a "hold" rating to a "buy" rating and set a $36.00 price objective for the company in a report on Tuesday, August 12th. Bank of America upped their price target on shares of Amphastar Pharmaceuticals from $28.00 to $32.00 and gave the stock a "neutral" rating in a research report on Tuesday, August 26th. JPMorgan Chase & Co. restated a "neutral" rating and set a $30.00 price target (down previously from $45.00) on shares of Amphastar Pharmaceuticals in a research note on Monday, May 12th. Finally, Piper Sandler lowered their target price on shares of Amphastar Pharmaceuticals from $30.00 to $25.00 and set a "neutral" rating for the company in a report on Friday, August 8th. Two investment analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. Based on data from MarketBeat, the company presently has an average rating of "Hold" and a consensus price target of $31.60.

About Amphastar Pharmaceuticals

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.